iomedicine.com/leadership#Warmuth">Markus Warmuth, M.D., President and Chief Executive Officer, H3 Biomedicine. "Both H3 Biomedicine and Selvita value early validation of drug targets to achieve preclinical proof of concept followed by translation of these findings into novel therapies for targeted patient populations. This collaboration is a key tool in our arsenal as it brings Selvita's kinase biology platform and medicinal chemistry capabilities together with H3's expertise in target validation, bioinformatics and genomics analysis. We look forward to working with Selvita to ultimately bring efficacious medicines to patients."
Pawel Przewiezlikowski, Chief Executive Officer of Selvita, said, "We are delighted to enter into this collaboration with H3 Biomedicine, and to apply our kinase discovery platform to jointly advance target discovery. The unique target identification and validation competences of H3 will bring our discovery efforts to a new level."
Krzysztof Brzozka, Chief Scientific Officer of Selvita, added "Both H3 and Selvita teams have always strived to identify novel therapeutic solutions for people living with cancer and we are very pleased that we can now join forces. This collaboration will enable us to significantly increase the breadth and depth of our pipeline."
About H3 Biomedicine Inc.
H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit http://www.h3biomedicine.com/ for more information.
About SelvitaPage: 1 2 3 Related biology technology :1
Selvita is a Polish biotechnology company engaged in the discovery and developme
. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights2
. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market3
. Cellular Biomedicine Group Announces Appointment of Corporate Controller4
. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis5
. Cellular Biomedicine Group Provides Update and 2013 Milestones6
. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors7
. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit8
. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification9
. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th10
. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances11
. A 300 Million Euro Boost for Biomedicine in Berlin